Ambrx Biopharma is a biotechnology business based in the US. Ambrx Biopharma shares (AMAM) are listed on the NASDAQ and all prices are listed in US Dollars. Ambrx Biopharma employs 87 staff and has a trailing 12-month revenue of around $4.1 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $25.85 |
| 200-day moving average | $18.23 |
| Wall St. target price | $28.67 |
| PE ratio | 66.6667 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.42 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Ambrx Biopharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ambrx Biopharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ambrx Biopharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 67x. In other words, Ambrx Biopharma shares trade at around 67x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Ambrx Biopharma's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
| Revenue TTM | $4.1 million |
|---|---|
| Gross profit TTM | $7.4 million |
| Return on assets TTM | -18.62% |
| Return on equity TTM | -37.23% |
| Profit margin | 0% |
| Book value | $3.85 |
| Market Capitalization | $1.8 billion |
TTM: trailing 12 months
We're not expecting Ambrx Biopharma to pay a dividend over the next 12 months.
You may also wish to consider:
Ambrx Biopharma's shares were split on 11 October 2023 .
Over the last 12 months, Ambrx Biopharma's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ambrx Biopharma's is -2.364. This would suggest that Ambrx Biopharma's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Ambrx Biopharma has bucked the trend.
To put Ambrx Biopharma's beta into context you can compare it against those of similar companies.
Ambrx Biopharma Inc. , a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California. As of March 7, 2024, Ambrx Biopharma Inc. operates as a subsidiary of Johnson & Johnson.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.